trending Market Intelligence /marketintelligence/en/news-insights/trending/C_6YFaOsGgMtZEBwBHoWqw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Monopar Therapeutics files for Nasdaq IPO

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Monopar Therapeutics files for Nasdaq IPO

Monopar Therapeutics LLC filed a prospectus with the U.S. Securities Exchange Commission for an IPO of its common shares to raise about $40.3 million.

The Illinois-based company has applied to list its shares on the Nasdaq Capital Market under the symbol MNPR.

Monopar Therapeutics, founded in 2014, plans to use the proceeds from the IPO to advance Validive, a medicine being developed to treat a complication arising from chemotherapy or radiotherapy in patients receiving treatment for oropharyngeal cancer.

JonesTrading Institutional Services LLC is the underwriter for the IPO.